StockNews.com Upgrades Intellia Therapeutics (NASDAQ:NTLA) to “Sell”

Intellia Therapeutics (NASDAQ:NTLA) was upgraded by research analysts at StockNews.com to a “sell” rating in a research note issued on Thursday.

Several other analysts have also commented on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $65.00 price objective on shares of Intellia Therapeutics in a report on Monday, June 24th. Citigroup cut their price target on Intellia Therapeutics from $31.00 to $29.00 and set a “neutral” rating for the company in a research note on Friday, May 10th. BMO Capital Markets increased their price objective on shares of Intellia Therapeutics from $62.00 to $70.00 and gave the stock an “outperform” rating in a research note on Friday, May 10th. Wedbush restated a “neutral” rating and set a $29.00 target price on shares of Intellia Therapeutics in a research report on Tuesday, April 23rd. Finally, Truist Financial reaffirmed a “buy” rating and set a $120.00 target price on shares of Intellia Therapeutics in a report on Monday, June 24th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat, Intellia Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $69.00.

Intellia Therapeutics Stock Performance

NTLA opened at $22.38 on Thursday. The company’s 50-day simple moving average is $23.76 and its two-hundred day simple moving average is $26.32. The stock has a market capitalization of $2.16 billion, a P/E ratio of -4.18 and a beta of 1.84. Intellia Therapeutics has a 52-week low of $19.37 and a 52-week high of $46.50.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($1.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.35) by $0.29. Intellia Therapeutics had a negative net margin of 893.34% and a negative return on equity of 45.35%. The company had revenue of $28.94 million for the quarter, compared to the consensus estimate of $15.60 million. Research analysts forecast that Intellia Therapeutics will post -4.98 EPS for the current fiscal year.

Hedge Funds Weigh In On Intellia Therapeutics

Several large investors have recently made changes to their positions in NTLA. ARK Investment Management LLC raised its stake in Intellia Therapeutics by 14.7% during the 4th quarter. ARK Investment Management LLC now owns 11,412,449 shares of the company’s stock valued at $347,966,000 after purchasing an additional 1,463,820 shares during the period. Vanguard Group Inc. raised its position in shares of Intellia Therapeutics by 8.9% during the first quarter. Vanguard Group Inc. now owns 9,093,712 shares of the company’s stock valued at $250,168,000 after buying an additional 746,263 shares during the last quarter. Wellington Management Group LLP lifted its holdings in shares of Intellia Therapeutics by 1.4% in the third quarter. Wellington Management Group LLP now owns 2,651,994 shares of the company’s stock worth $83,856,000 after buying an additional 36,630 shares in the last quarter. Federated Hermes Inc. boosted its position in shares of Intellia Therapeutics by 13.8% during the fourth quarter. Federated Hermes Inc. now owns 2,016,300 shares of the company’s stock worth $61,477,000 after acquiring an additional 244,722 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in Intellia Therapeutics by 5.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,170,829 shares of the company’s stock valued at $35,704,000 after acquiring an additional 60,748 shares in the last quarter. 88.77% of the stock is currently owned by hedge funds and other institutional investors.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.